Page 352 - Read Online

Page 30 of 31 Paul J Cancer Metastasis Treat 2020;6:29 I http://dx.doi.org/10.20517/2394-4722.2020.63

184. Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol 2017;118:79-83.
185. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from
bench and bedside. Blood 2012;119:924-32.
186. Magnus N, Garnier D, Meehan B, McGraw S, Lee TH, et al. Tissue factor expression provokes escape from tumor dormancy and leads to
genomic alterations. Proc Natl Acad Sci U S A 2014;111:3544-9.
187. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood
2008;111:190-9.
188. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous
dissemination. Cancer Discov 2012;2:1091-9.
189. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition
and promotes metastasis. Cancer Cell 2011;20:576-90.
190. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010;20:169-77.
191. Becker KA, Beckmann N, Adams C, Hessler G, Kramer M, et al. Melanoma cell metastasis via P-selectin-mediated activation of acid
sphingomyelinase in platelets. Clin Exp Metastasis 2017;34:25-35.
192. Lavergne M, Janus-Bell E, Schaff M, Gachet C, Mangin PH. Platelet integrins in tumor metastasis: do they represent a therapeutic target?
Cancers (Basel) 2017;9.
193. Mege D, Panicot-Dubois L, Ouaissi M, Robert S, Sielezneff I, et al. The origin and concentration of circulating microparticles differ
according to cancer type and evolution: a prospective single-center study. Int J Cancer 2016;138:939-48.
194. Mezouar S, Frere C, Darbousset R, Mege D, Crescence L, et al. Role of platelets in cancer and cancer-associated thrombosis:
experimental and clinical evidences. Thromb Res 2016;139:65-76.
195. Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, et al. Tumor shedding and coagulation. Science 1981;212:923-4.
196. Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, et al. Microvesicle-associated tissue factor and Trousseau’s
syndrome. J Thromb Haemost 2007;5:70-4.
197. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood
2013;122:1873-80.
198. Magnon C. Role of the autonomic nervous system in tumorigenesis and metastasis. Mol Cell Oncol 2015;2:e975643.
199. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and
the immune system. Pharmacol Rev 2000;52:595-638.
200. Li T, Harada M, Tamada K, Abe K, Nomoto K. Repeated restraint stress impairs the antitumor T cell response through its suppressive
effect on Th1-type CD4+ T cells. Anticancer Res 1997;17:4259-68.
201. Cao L, Liu X, Lin EJ, Wang C, Choi EY, et al. Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer
remission and inhibition. Cell 2010;142:52-64.
202. Burfeind KG, Michaelis KA, Marks DL. The central role of hypothalamic inflammation in the acute illness response and cachexia. Semin
Cell Dev Biol 2016;54:42-52.
203. Braun TP, Zhu X, Szumowski M, Scott GD, Grossberg AJ, et al. Central nervous system inflammation induces muscle atrophy via
activation of the hypothalamic-pituitary-adrenal axis. J Exp Med 2011;208:2449-63.
204. Burfeind KG, Zhu X, Levasseur PR, Michaelis KA, Norgard MA, et al. TRIF is a key inflammatory mediator of acute sickness behavior
and cancer cachexia. Brain Behav Immun 2018;73:364-74.
205. Mravec B, Horvathova L, Cernackova A. Hypothalamic inflammation at a crossroad of somatic diseases. Cell Mol Neurobiol 2019;39:11-29.
206. Molfino A, Iannace A, Colaiacomo MC, Farcomeni A, Emiliani A, et al. Cancer anorexia: hypothalamic activity and its association with
inflammation and appetite-regulating peptides in lung cancer. J Cachexia Sarcopenia Muscle 2017;8:40-7.
207. Mauffrey P, Tchitchek N, Barroca V, Bemelmans AP, Firlej V, et al. Progenitors from the central nervous system drive neurogenesis in
cancer. Nature 2019;569:672-8.
208. Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment.
Nat Rev Cancer 2015;15:563-72.
209. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, et al. Regulation of cancer cell migration and bone metastasis by
RANKL. Nature 2006;440:692-6.
210. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, et al. Signals from the sympathetic nervous system regulate hematopoietic stem
cell egress from bone marrow. Cell 2006;124:407-21.
211. Elefteriou F. Role of sympathetic nerves in the establishment of metastatic breast cancer cells in bone. J Bone Oncol 2016;5:132-4.
212. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, et al. Autonomic nerve development contributes to prostate cancer progression. Science
2013;341:1236361.
213. Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Haheim LL. Use of beta-blockers is associated with prostate cancer-specific survival in
prostate cancer patients on androgen deprivation therapy. Prostate 2013;73:250-60.
214. Lemeshow S, Sorensen HT, Phillips G, Yang EV, Antonsen S, et al. Beta-blockers and survival among Danish patients with malignant
melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011;20:2273-9.
215. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, et al. Beta-blocker use is associated with improved relapse-free
survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29:2645-52.
216. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex--linking immunity and metabolism. Nat Rev Endocrinol 2012;8:743-
54.
217. Fujii T, Mashimo M, Moriwaki Y, Misawa H, Ono S, et al. Expression and function of the cholinergic system in immune cells. Front
Immunol 2017;8:1085.